From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
  • AU: C
Routes of
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolism Hepatic (mostly via conjugation)[1]
Biological half-life 12 h[1]
Excretion Renal[1]
CAS Number
PubChem CID
ECHA InfoCard 100.018.248
Chemical and physical data
Formula C21H23N3OS
Molar mass 365.49 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Periciazine (INN), also known as pericyazine (BAN) or propericiazine, is a drug that belongs to the phenothiazine class of typical antipsychotics.

Pericyazine is not approved for sale in the United States. It is commonly sold in Canada and Russia under the tradename Neuleptil and in United Kingdom and Australia under the tradename Neulactil.[2]

Medical Uses[edit]

The primary uses of pericyazine include in the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia. There is insufficient evidence to determine whether periciazine is more or less effective than other antipsychotics.[1][3]

Periciazine has also been studied in the treatment of opioid dependence.[4]

Adverse effects[edit]

Pericyazine is a rather sedating and anticholinergic antipsychotic, and despite being classed with the typical antipsychotics, its risk of extrapyramidal side effects is comparatively low.[5] It has a relatively high risk of causing hyperprolactinaemia and a moderate risk of causing weight gain and orthostatic hypotension.[5]


  1. ^ a b c d "NEULACTIL PRODUCT INFORMATION" (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. 13 September 2011. Retrieved 2 November 2013. 
  2. ^ Pericyazine. Martindale: The Complete Drug Reference. The Royal Pharmaceutical Society of Great Britain. 23 September 2011. Retrieved 2 November 2013. 
  3. ^ Leucht S, Helfer B, Hartung B. Perazine for schizophrenia. Cochrane Database Syst Rev. 2014 Jan 15;1:CD002832. Review. doi:10.1002/14651858.CD002832.pub3 PMID 24425538
  4. ^ Sivolap IuP, Savchenkov VA (1999). "[The use of neuroleptics in treating opiate dependence]". Zh Nevrol Psikhiatr Im S S Korsakova (in Russian). 99 (6): 29–34. PMID 10441864. 
  5. ^ a b "Approximate relative frequency (not intensity) of common adverse effects of antipsychotics (Table 8.21) [NB1]". eTherapeutic Guidelines complete. Therapeutic Guidelines Limited. February 2013. Retrieved 2 November 2013. 

External links[edit]